Bristol-Myers Squibb 4Q09 4Q Revenues: $5.0 billion (+11%) 4Q Earnings: $1.1 billion (-19%) FY Revenues: $18.8 billion (+6%) FY Earnings: $4.4 billion (+20%) Comments: BMS’s share of Plavix sales rose 10% in 4Q09 and FY09 to $1.6 billion and $6.1 billion, respectively. Orencia sales grew 37% in FY09 to $602 million, nod Sprycel was up 36% to $421 million. Erbitux royalties dropped 9% to $683 million for the year. R&D expenses dropped slightly to $1.1 billion in 4Q09, and...